A Study to Evaluate the Impact of Liquid Biopsy in Participants With a

Status Recruiting

Clinical Trial Summary

This is an international, prospective study to assess the impact of concomitant early use of liquid biopsy (FoundationOne® Liquid CDx) within the diagnostic pathway, compared with the standard of care diagnostic pathway, on the timing of routine cancer care in treatment-naïve participants presenting with a clinical diagnosis of advanced cancer, where the pathologic diagnosis has not yet been confirmed. Participants with one of the following two clinical presentations will be included: participants with evidence of de novo metastatic lung cancer or participants with evidence of de novo metastatic gastrointestinal cancer. Participants may have undergone different levels of diagnostic workup prior to enrollment. Participants who have not had tissue biopsy performed prior to enrollment will be classified as 'basic workup' and those who have had tissue biopsy performed prior to enrollment will be classified as 'extended workup'. During the diagnosis period, eligible participants will undergo liquid biopsy (FoundationOne® Liquid CDx assay; as per label) on blood samples. Blood samples will be tested using the FoundationOne® Liquid CDx assay at a central laboratory. In parallel, participants will undergo the standard of care diagnostic pathway, including tissue biopsy and histology workup, if not already done before enrollment, and molecular workup according to ESMO guidelines or national guidelines for each tumor type included in this study. Once a complete pathologic diagnosis has been made, the investigator (or multidisciplinary team) can complete an anti-cancer treatment recommendation assessment. Anti-cancer treatment recommendation should follow current practice and professional guidelines based on the results provided by either liquid biopsy (as per label) or tissue biopsy/standard of care.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Gastrointestinal Neoplasms
Metastatic Gastrointestinal Cancer
Metastatic Lung Cancer

Clinical Trial Details

NCT number	NCT05846594
Study type	Interventional
Source	Hoffmann-La Roche
Contact	Reference Study ID Number: MO43989 https://forpatients.roche.com
Phone	888-662-6728 (U.S. Only)
Email	global-roche-genentech-trials@gene.com
Status	Recruiting
Phase	Phase 4
Start date	September 14, 2023
Completion date	November 15, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03177291` - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC	Phase 1
Not yet recruiting	`NCT03514329` - Vapor Ablation for Localized Cancer Lesions	N/A
Recruiting	`NCT05502913` - Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer	Phase 2
Recruiting	`NCT06060613` - Safety and Efficacy of OBX-115 in Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT00986661` - A Study to Assess PV-10 Chemoablation of Cancer of the Liver	Phase 1
Recruiting	`NCT05609578` - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation	Phase 2
Completed	`NCT01543672` - Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously	Phase 1/Phase 2
Completed	`NCT03198468` - Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)	N/A
Recruiting	`NCT06180460` - CALM: Managing Distress in Malignant Brain Cancer	N/A
Completed	`NCT04804137` - Immune Response Under Immunotherapy in Metastatic NSCLC: Sputum, Blood Samples and Microbioata Study
Recruiting	`NCT06343402` - Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer	Phase 1
Recruiting	`NCT04940325` - Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT05241873` - (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations	Phase 1/Phase 2
Recruiting	`NCT05256290` - Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations	Phase 1/Phase 2
Completed	`NCT05908799` - Emulation of the KEYNOTE-189 Trial Using Electronic Health Records
Active, not recruiting	`NCT03867175` - Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer	Phase 3
Recruiting	`NCT04708483` - DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria	N/A
Completed	`NCT01307501` - Safety and Efficacy of Cryoablation for Metastatic Lung Tumors	N/A
Recruiting	`NCT03143322` - Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases	N/A
Recruiting	`NCT05143970` - A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Study to Evaluate the Impact of Liquid Biopsy in Participants With a Clinical Diagnosis of Advanced Cancer — L1st

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms